Cohance Lifesciences Ltd. News and Updates

Name: Latest research reports of Cohance Lifesciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Cohance Lifesciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Keep track of all breaking news on Cohance Lifesciences Ltd. from all sources in a single place.

Load latest

Cohance Lifesciences Ltd.

24 Mar 2025

922.90

2.62%

[Initiation] A play on the ADC growth segment

Buy: Cohance Lifesciences Ltd.

BOB Capital Markets Ltd.

ADC is an evolving second line of treatment in oncology. The company expects market size to grow to US$ 50bn by FY33 from US$ 5bn in FY22

Promoters have increased holdings from 50.10% to 66.41% in Jun 2025 qtr.

Cohance Lifesciences Ltd.

03 Mar 2025

922.90

2.62%

Indian pharma's capability, regulatory compliance help to tap global CDMO space'

Business Line

The progress India has made in terms of building the capabilities and number of scientists work in its favour.Also, India has a much better regulatory record than how it was perceived about 7 and 8 years ago': Suven Pharma's Executive Chairman Vivek Sharma

Promoters have increased holdings from 50.10% to 66.41% in Jun 2025 qtr.

Cohance Lifesciences Ltd.

20 Feb 2025

922.90

2.62%

Suven Pharma soars 14% on heavy volumes; surges 43% from January low

Business Standard

Suven Pharma is set to benefit from high-growth cutting-edge CDMO segments and its proven track record to drive traditional business.

Cohance Lifesciences Ltd. has lost -20.69% in the last 6 Months

Cohance Lifesciences Ltd.

20 Feb 2025

922.90

2.62%

Macquarie initiates outperform rating on 4 Indian pharma stocks, sees 19-35% upside. Here's why

livemint

Indian pharma stocks: Macquarie favours Indian CDMOs, notably Divi's Labs and Suven Pharma, highlighting their superior scale and customer relationships. The Indian CRDMO market is projected to grow from US$7 billion to US$14 billion by 2028, driven by increased pharmaceutical outsourcing.

Cohance Lifesciences.. has an average target of 1346.50 from 2 brokers.

Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and Syngene

Economic Times | 20 Feb 2025

Cohance Lifesciences Ltd.

13 Feb 2025

922.90

2.62%

Suven Pharma shares zooms 12% on strong Q3 nos; PAT up 78%, rev 39%

Business Standard

Suven Pharma reported a 78 per cent rise in consolidated net profit during the third quarter to Rs 83.29 crore, as compared to Rs 46.75 crore in Q3FY24

Promoters have increased holdings from 50.10% to 66.41% in Jun 2025 qtr.

Cohance Lifesciences Ltd.

12 Feb 2025

922.90

2.62%

Suven Pharmaceuticals Results Earnings Call for Q3FY25

Conference Call with Suven Pharmaceuticals Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.

Cohance Lifesciences Ltd.

27 Jan 2025

922.90

2.62%

Suven Pharma looks for 6x increase in revenue by FY35

Business Today

Looking to the future, Suven's Horizon 2 initiative which includes plans to incorporate capabilities in flow chemistry, messenger ribonucleic acid (mRNA), and peptides by fiscal year 2030 is expected to enhance the company's position in advanced drug modalities.

Cohance Lifesciences.. has an average target of 1346.50 from 2 brokers.

Cohance Lifesciences Ltd.

10 Dec 2024

922.90

2.62%

How Will NJ Bio Acquisition Aid Suven Pharma?

NDTV Profit

We've seen an increase in enquiries on the back of China-free strategy, says Suven Pharma Executive Chairman Vivek Sharma. #suvenpharmanews #stockmarketnews